|
Final Programme
PDF Version
**Keynote Lectures In Bold
SATURDAY, JULY 31
12-5pm Check-in and Registration
Conference Office, 10 Buick Street,
Ground Floor, Room G15
SUNDAY, AUGUST 1
8:45am Welcome Carol Black
Robert Lafyatis
Session 1 (9:00-10)
Challenges & Advances in Systemic Sclerosis
Chair J Varga
9:00 Challenges facing the clinician D Furst
9:30 Advances in scleroderma and the Workshop C Denton
10:00 Coffee Break
Session 2 (10:30-12)
Genetic Associations in Scleroderma: GWAS Studies
Chair Josephine Hoh
10:30 Genetic associations in systemic sclerosis M Mayes
10:50 Immune genetics in systemic sclerosis T Radstake
11:10 Genetics & biomarkers in systemic sclerosis P Pantelidis
11:30 Discussion
12:00-1:30 Lunch
Session 3 (1:30-3:00)
Genetic Regulation in Pulmonary Disease
Chair F Arnett & B Kahaleh
Keynote
1:30 Gene regulation in interstitial lung disease K Gibson
2:00 micro RNAs and TGFβ A Hata
2:20 Lessons from gene expression in pulmonary hypertension T Bull
2:40 Discussion
3:00 Tea
Session 4
Genetic Markers in Systemic Sclerosis
3:30 Subclassification of scleroderma patients using microarray gene
expression M Whitfield
3:50 Interferon-regulated gene expression in systemic sclerosis S Assassi
4:10 Discussion
4:30-5:30 Poster Session (Authors stand by posters)
18th Floor Lounge, 10 Buick Street
5:30-7:00 Welcome Reception Agganis Arena
Burke Club Room
Free Evening
MONDAY, AUGUST 2 (Please note: All Monday sessions are in the Burke Club
Room, 2nd floor of Agganis Arena)
Session 5 (9:00-10:30) Agganis Arena Burke Club
Room
Pulmonary Fibrosis Clinical Update & Pathogenesis
Chair F Wollheim & T Wynn
Keynote
9:00 Oxidative stress, hemoxygenase, cell apoptosis and lung injury A Choi
9:30 Clinical radiological correlations in pulmonary fibrosis A Wells
9:50 Inflammasome and innate immunity in pulmonary fibrosis F Sutterwala
10:10 Discussion
10:30 Coffee Break
Session 6 (11:00-12:00) Agganis Arena Burke Club Room
Mediators of Fibrotic Lung Disease
Chair A Choi & A Wells
Keynote
11:00 Matrix and proteases in fibrosis G Laurent
11:30 IGFBP5 and gene regulation in scleroderma-associated pulmonary
fibrosis C Feghali-Bostwick
11:50 Discussion
12:00 Lunch
Abstract Presentations (1-2:40)
Agganis Arena - Burke Club Room
Chair L Mouthon
1:00 Inhibition of thrombin as a novel strategy in the treatment of
scleroderma-associated ILD Bogatkevich
1:20 Genetic deletion or pharmacologic antagonism of LPA1 ameliorates dermal
fibrosis in a mouse model of systemic sclerosis Castelino
1:40 Post-natal fibroblast-specific deletion of the Pten gene in fibroblasts
induces a scleroderma phenotype Parapuram
2:00 Semaphorin 7a regulates fibrocyte accumulation in TGF- ฿1 induced
pulmonary fibrosis Herzog
2:20 The early growth response gene Egr-2 (Krox20) is a novel
transcriptional target of transforminggrowth factor-β that is up-regulated
in systemic sclerosis and mediates profibrotic responses Feng
3:00 Tea
Session 7 (3:20-5:00) Agganis Arena Burke Club Room
Emerging Therapeutics I
Chair R Simms & M Baron
3:20 Targeting B cells and IFN in scleroderma B White
3:40 SAP in fibrosis M Lupher
4:00 Actemra (Tocilizumab) J Pope
4:20 Tyrosine kinase inhibitors in SSc P Gergely
4:40 Discussion
Session 8 (5:20-6:40) Agganis Arena Burke Club
Room
Emerging Therapeutics II
Chair M Matucci Cerinic & T Medsger
5:20 Anti- αvβ6 S Violette
5:40 Anti-TGFβ J Mannick
6:00 miRNA therapeutics TBA
6:20 Discussion
Free Evening
TUESDAY, AUGUST 3
Session 9 (8:30-10)
Mechano-sensing in Fibrosis
Chair K Rubin & T Krieg
Keynote
8:30 Mechano-sensing in fibrosis D Ingber
9:00 Myofibroblasts & fibrosis D Tschumperlin
9:20 Integrin regulation of fibroblast phenotype B Eckes
9:40 Discussion
10:00 Coffee Break
Session 10 (10:40-12)
Inflammation & Fibrosis
Chairs- R Lafyatis & A Postlethwaite
10:40 T cells in graft versus host disease S Katz
11:00 Immune activation & fibrosis A Coyle
11:20 IL-13 & alternative macrophage activation T Wynn
11:40 Discussion
12-1:30 Lunch
Session 11 (1:30-3)
Progenitors, Stem Cells & Regenerative Medicine
Chair - D Abraham & S Jim้nez
Keynote
1:30 Wnt regulation of fibrosis T Rando
2:00 IPS cells & lung regeneration D Kotton
2:20 PPARin mesenchymal cell differentiation J Varga
2:40 Discussion
3:00 Tea
Session 12 (3:30-5)
Pulmonary Arterial Hypertension
Chair H Farber & L Mouthon
Keynote
3:30 Pathogenic mechanisms in pulmonary hypertension R Tuder
4:00 IL-6 in pulmonary hypertension A Waxman
4:20 Altered endothelial cells M Trojanowska
in scleroderma vasculopathy
4:40 Discussion
6-9 Dinner Banquet Metcalf Trustee
Center Ballroom, 1 Silber Way
Speaker: Robert F. Meenan, MD, MPH, MBA
Dean, Boston University
School of Public Health
WEDNESDAY, AUGUST 4
Session 13 (8:30-10)
Vascular Inflammation & Injury
Chair A Gabrielli & R Tuder
Keynote
8:30 Pulmonary arterial hypertension - Lessons from new models M Rabinovitch
9:00 The immune response in PAH G Grunig
9:20 Anti-endothelial cell antibodies & oxidative stress in scleroderma F
Batteux
9:40 Discussion
10:00 Coffee Break
Session 14 (10:30-12)
Regulation of Vascular Phenotype
Chair M Rabinovitch & M Trojanowska
Keynote
10:30 Vascular inflammation J Loscalzo
11:00 Endothelial mesenchymal transition S Jim้nez
11:20 EPCs and manufacturing vascular networks in vivo J Bischoff
11:40 Discussion
12-1:20 Lunch
Session 15 (1:20-4)
Scleroderma Clinical Trials Consortium Session
Chairs J Seibold & R Simms
1:20 Development of outcome measures in CTD-ILD L Saketkoo
2:00 Trial design for SSc-ILD A Wells
2:20 Lung &blood biomarkers in SSc-ILD C Feghali-Bostwick
3:00 Lessons learned from recent trials J Seibold
3:20 Utilization of skin biomarkers in SSc clinical trials R Lafyatis
3:40 Discussion
|
